Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes

Infection and Immunity

Volumn 77, Issue 7, 2009, Pages 2795-2801

  Shone, Clifford ^a   Agostini, Heidi ^b   Clancy, Joanna ^b   Gu, Mili ^b   Yang, Huei Hsiung ^b   Chu, Yanfang ^b   Johnson, Virginia ^b   Taal, Makie ^a   McGlashan, Joanna ^a   Brehm, John ^a   Tong, Xiaomi ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Emergent Biosolutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; LUTEINIZING HORMONE; NEUROTOXIN; NEUROTOXIN TYPE A; NEUROTOXIN TYPE B; POLYPEPTIDE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNIZATION; MOUSE; NERVE CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BOTULISM; ESCHERICHIA COLI; GENE EXPRESSION; MICE; MODELS, MOLECULAR; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 67650096394     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01252-08     Document Type: Article

References (31)

1. 4. J. Mol. Biol. 362:733-742.
2. Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, and K. Tonat. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
3. Byrne, M. P., and L. A. Smith. 2000. Development of vaccines for prevention of botulism. Biochemie 82:955-966.
4. Byrne, M. P., T. J. Smith, V. A. Montgomery, and L. A. Smith. 1998. Purification, potency and efficacy of a botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66:4817-5011.
5. Chaddock, J. A., M. H. Herbert, R. J. Ling, F. C. Alexander, S. J. Fooks, D. F. Revell, C. P. Quinn, C. C. Shone, and K. A. Foster. 2002. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25:219-228.
6. Dolly, J. O., J. Black, R. S. Williams, and J. Melling. 1984. Acceptors for botulinum neurotoxins reside on the motor nerve surface and mediate its internalisation. Nature 307:457-460.
7. Dong, M., F. Yeh, W. H. Tepp, C. Dean, E. A. Johnson, R. Janz, and E. R. Chapman. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
8. Enami, I., M. Kamo, H. Ohta, S. Takahashi, T. Miura, M. Kusayanagi, S. Tanabe, A. Kamei, A. Motoki, M. Hirano, T. Tomo, and K. Satoh. 1998. Intramolecular cross-linking of the extrinsic 33-kDa protein leads to loss of oxygen evolution but not its ability of binding to photosystem II and stabilization of the manganese cluster. J. Biol. Chem. 273:4629-4634.
9. Fiock, M., M. A. Cardella, and N. F. Gearringer. 1963. Studies on the immunity of Clostridium botulinum: immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J. Immunol. 90:697-702.
10. Foster, K. A., E. J. Adams, L. Durose, C. J. Cruttwell, E. Marks, C. C. Shone, J. A. Chaddock, C. L. Cox, C. Heaton, J. M. Sutton, J. Wayne, F. C. Alexander, and D. F. Rogers. 2006. Re-engineering the target specificity of clostridial neurotoxins: a route to novel therapeutics. Neurotoxin Res. 9:101-107.
11. Hallis, B., S. Fooks, C. C. Shone, and P. Hambleton. 1993. Characterization of monoclonal antibodies to BoNT/A, p. 433-436. In B. DasGupta (ed.), Botulinum and tetanus neurotoxins. Plenum Press, Inc., New York, NY.
12. Hallis, H., B. A. F. James, and C. C. Shone. 1996. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol. 34:1934-1938.
13. Hill, K. K., T. J. Smith, C. H. Helma, L. O. Ticknor, B. T. Foley, R. T. Svensson, J. L. Brown, E. A. Johnson, L. A. Smith, R. T. Okinaka, P. J. Jackson, and J. D. Marks. 2007. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 189:818-832.
14. Hudecz, F. 2001. Manipulation of epitope function by modification of peptide structure: a minireview. Biologicals 29:197-207.
15. Jensen, M. J., T. J. Sith, S. A. Ahmed, and L. A. Smith. 2003. Expression, purification and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41:691-701.
16. Jin, R., A. Rummel, T. Binz, and A. Brunger. 2006. Botulinum type B recognizes its protein receptor with high affinity and specificity. Nature 444:1092-1095.
17. Lacy, B., W. Tepp, A. C. Cohen, B. R. DasGupta, and R. C. Stevens. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898-902.
18. Metz, B., G. F. Kersten, P. Hoogerhout, H. F. Brugghe, H. A. Timmermans, A. de Jong, H. Meiring, J. ten Hove, W. E. Hennink, D. J. Crommelin, and W. Jiskoot. 2004. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J. Biol. Chem. 279:6235-6243.
19. Minton, N. P. 1995. Molecular genetics of clostridial neurotoxins. Curr. Top. Microbiol. Immunol. 195:161-194.
20. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R., Blake, L.A Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346-11350.
21. Pier, C. L., W. H. Tepp, M. Bradshaw, E. A. Johnson, J. T. Barbieri, and M. R. Baldwin. 2008. Recombinant holotoxoid vaccine against botulism. Infect. Immun. 76:437-442.
22. Putz, M. M., J. Hoebeke, W. Ammerlaan, S. Schneider, and C. P. Muller. 2003. Functional fine-mapping and molecular modeling of a conserved loop epitope of the measles virus hemagglutinin protein. Eur. J. Biochem. 270:1515-1527.
23. Rummel, A., S. Mahrhold, H. Bigalke, and T. Binz. 2004. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51:631-643.
24. Schiavo, G., M. Matteoli, and C. Montecucco. 2000. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80:717-766.
25. Shone, C. C., and H. S. Tranter. 1995. Growth of clostridia and preparation of their neurotoxins. Curr. Top. Microbiol. Immunol. 195:143-160.
26. Shone, C. C., P. Hambleton, and J. Melling. 1985. Inactivation of Clostridium botulinum type A neurotoxin with trypsin and purification of two tryptic fragments. Eur. J. Biochem. 151:75-82.
27. Smith, L. A., and J. M. Rusnak. 2007. Botulinum neurotoxin vaccines: past present and future. Crit. Rev. Immunol. 27:301-318.
28. Studier, F. W. 2005. Protein production by auto-induction in high density shaking cultures. Prot. Expr. Purif. 41:207-234.
29. Sutton, J. M., J. Wayne, A. Scott-Tucker, S.M. O'Brien, P. M. Marks, F. C. Alexander, C. C. Shone, and J. A. Chaddock. 2005. Preparation of specifically activatable endopeptidase derivatives of Clostidium botulinum types A, B, and C and their applications. Prot. Expr. Purif. 40:31-41.
30. Swaminathan, S., and S. Eswaramoorthy. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693-699.
31. Vani, K., S. A. Bogen, and S. R. Sompuram. 2006. A high throughput combinatorial library technique for identifying formalin-sensitive epitopes. 2006. J. Immunol. Methods 317:80-89.